Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 3Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 118Specimen Handling 104pembrolizumab 103Magnetic Resonance Spectroscopy 95fludarabine 93Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 37Paclitaxel 35Cetuximab 35Carboplatin 35Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Gemcitabine 29Leucovorin 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20130-nm albumin-bound paclitaxel 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × aumolertinib × Clear all
NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡